biotech investment showcase · pdf file · 2017-10-12novartis john haurum f-star...
TRANSCRIPT
For Booking details and registration fees, please email [email protected] or visit
www.biotechinvestment-showcase.com
BIOTECH INVESTMENT
SHOWCASE
&
START UP SLAM 2018
22-23 May 2018
London, UK
2018 Biotech Investor Showcase and Start-up Slam, 22nd- 23rd May 2018, London
The 2018 Biotech Investment showcase is the UK and Europe's most focussed and leading-edge funding,
investment and partnering forum in the biotech sector, hosting over 300 attendees. Leading VC funds,
pharma investors, hedge funds, emerging successful biotech spinoffs, early stage biotech discovery and
clinical companies as well as KOLs in the sector will be attending this one of a kind showcase event on
the 22nd & 23rd May 2018 in London. The event will help to identify the key technological and scientific
investment areas in the sector and will also offer a unique networking, partnering and business
development opportunity for those involved.
What does the showcase consist of?
Biotech Investment Conference Speakers, and Start up Slam Judging Faculty
Biotech Investment conference
programme and showcase
• An educational programme
with over 60 presentations,
postulating topics on scientific,
technological and investment
growth in the industry
• Over 50 biotech spinoffs,
early stage discovery and clinical
company product presentations
during the 2 days
• Two dedicated Startup Slam
Sessions and supported by a 20-
strong judging expert faculty
Networking opportunities &
scheduled business partnering
meetings
• Over 35 Scheduled business
partnering meetings
• Exhibition area with coffee
and lunch breaks
• Poster presentation
spotlights
• Pre-dinner reception and
networking drinks
Corporate Gala Dinner and
Awards
• Gala dinner and awards
ceremony featuring the best
scientist award categories
• Live polling throughout the
dinner on industry hot topics
• Supporting Cancer
Research UK through each event
evaluation form received
Start Up Slam
At the showcase event, there are two dedicated sessions on the agenda for start-up entrepreneurs or
scientists like yourselves to present your new product and research in front of leading pharma and
biotech venture companies, VCs and Technology Transfer offices.
If you are developing an innovative product or technology in the following areas, please email
• NGS/Single Cell/Genomics Technologies/dPCR/Microfluidics
• Microbiome Discovery and Development
• Artificial Intelligence and Digital Health
• Immuno-Oncology and Immuno-Therapy
• Biomarkers/Precision Medicine/ Liquid Biopsy
Lori L. Badura,
EMD EMD Serono
Melanie Goward
Malvern Capital
Partners
Maciek Drozdz,
Johnson & Johnson Bent Jakobsen,
Immunocore Olga Krylova
Pfizer Mouad Lamrani
Menicon Co., Ltd
Paul-Peter Tak
GSK Timothy Herpin
Astra Zeneca Torsten Hoffmann
Silence
Therapeutics
Yiu-Lian Fong,
Johnson &
Johnson
Tony Hickson
Imperial Innovations
Ltd
Avi Spier
Novartis
John Haurum
F-star
Lothar Germeroth
Juno Therapeutics
Rakesh Dixit
Medimmune
Philip Arlen
Precision Biologics
Richard Sainson
Kymab
Kristin Wannerberger
Ferring
Biotech Investment Conference Speakers, and Start up Slam Judging Faculty includes:
• Paul-Peter Tak, Senior Vice President R&D Pipeline, Global Development Leader and Chief
Immunology Officer, GSK (Reserved)
• Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer
• Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment,
Medimmune
• Yiu-Lian Fong, Global Head Diagnostic Innovation, Research and Early Development, Johnson and
Johnson
• Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance
Management, EMD Serono
• Morten Lindow, Director, Innovation and Project Excellence, Roche (Reserved)
• Bent Jakobsen, Chief Scientific Officer, Immunocore
• Deborah A. O’Neil, Chief Executive & Scientific Officer, Novabiotics
• Christopher Roberts, Associate Director of Computational Biology, Biogen Idec (Reserved)
• Timothy Herpin, Vice President, Head of Transactions Business Development, Astra Zeneca
• Kristin Wannerberger, Director R&D Alliance Management, Ferring International Center S.A
• Bernhard Paetzold, Founder, S-Biomedic
• Mouad Lamrani, Director of R&D Innovation Center, Menicon Co., Ltd
• Maciek Drozdz, Principal of Venture Investments, Johnson and Johnson Development Corporation
• Avi Spier, Director, NIBR BD&L, Search and Evaluation, CVM, GDC, CBT Chem-Bio, GNF Systems and
Microbiome, Novartis (Reserved)
• Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics
• Tommi Lehtonen, CEO, Blueprint Genetics
• Melanie Goward, Investment Director, Maven Capital Partners UK LLP
• Vijay Barathan, Life Science Partner, Catapult Ventures(Reserved)
• Tony Hickson, MD, Imperial Innovations Ltd
• Davide Danovi, Director, HipSci Cell Phenotyping, Centre for Stem Cells & Regenerative Medicine,
King's College London
• Patrice Garnier, CEO, AMABIOTICS
• Michael Fraser, VP University Relations, Queen's University(Reserved)
• Patrick Gillevet, Professor, Director, George Mason University, Director of the Microbiome Analysis
Center
• Lothar Germeroth, Senior Vice President, Managing Director, Juno Therapeutics GmbH
• Andreas Kungl, CEO, Antagonis
• Natasha Carli, Genomics Core Director, Gladstone Institutes(Reserved)
• Assaf Oron, Chief Business Officer, BioimX(Reserved)
• Pierre-Jean Ripoll, Director R&D France, Pharming Group
• Ron Alfa, VP of Discovery and Product, Recursion Pharmaceuticals (Reserved)
• Mihriban Tuna, Vice President, Drug Discovery, F-star Biotechnology Ltd.
• John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.
• Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.
• Richard C.A. Sainson, Director in Pharmacology and Translational Sciences, Kymab
DAY 1 – Stream 2
Microbiome Discovery and Development
➢ Machine learning and Data Analysis
➢ AI application in Pharma R&D
➢ High-throughput screening and AI
➢ Genomics, Big Data Analysis and Deep Learning
➢ AI in Drug Design and development
➢ AI and Precision medicine
➢ Translational informatics
➢ AI in Cloud computing and Big data
➢ Supporting Real World Evidence and E Health Support
➢ AI, Robotics and Machine Learning: leading data science and
machine learning
➢ Integrated Healthcare and Digital health
➢ Medical devices and digital healthcare solutions
DAY 1 – Stream 1
NGS/Genomics Technologies/dPCR/Microfluidics
bccghck
DAY 1 – Stream 3
Pharma Technologies, Artificial Intelligence, Medical Devices
and Digital Health
➢ Innovations of NGS in pharma: biomarker development,
precision medicine and clinical diagnostics
➢ NGS, genomics and clinical diagnostics in healthcare
➢ NGS Data Analysis & NGS Application Strategies
➢ Single Cell ‘Omics Analysis: Current and Emerging Tools
➢ Single Cell Analysis - Translation to Diagnostic and Therapeutic
Applications
➢ Single Cell Data Analysis & Advances in Microfluidic
Technologies
➢ Microbiome Discovery & Technologies
➢ Translational Science of the Microbiome
➢ Novel Genomic Technologies
➢ Next Generation Sequencing technologies
➢ Data Management in Microbiome Discovery
➢ Bacterial Pathogens and the Microbiome
➢ Small Molecule Microbiome Discovery
➢ Discovery and development of Microbiome Therapeutics in
Metabolic Disorders, Inflammatory Conditions, Women’s
Health, Dysbiosis
➢ Immune monitoring
➢ Clinical trial design and management
➢ Translational biomarkers
➢ Microbiome and Immuno-oncology
➢ Cancer Immunoassays for biomarker development
➢ Drug development partnerships
➢ Immuno-oncology Therapeutic Development
DAY 2 – Stream 1
Immuno-Oncology and Immuno- Therapy – Discovery and
Development
➢ Precision Medicine, Companion Diagnostics, Molecular
Diagnostics Development
➢ Innovations in Biomarkers Research, Assay
Development, Imaging, Data Integration Methods,
Bioinformatics, Trial Design
➢ Innovative Biology- NGS & Genomic Markers, Clinical
Testing and Diagnostics Development
➢ Genomic approaches in drug development
➢ Advances made in NGS techniques in liquid biopsy
➢ RNAseq NGS in biomarker benchmarking
BIOTECH INVESTMENT PROGRAMME AND SHOWCASE TOPICS
Day 2 - Stream 2
Proteins, Antibodies, Cell based Biotherapeutic Development
Gain insights and learn from over 60 expert speakers from pharmaceutical, biotech, academic, medical devices and
investment companies
Assessing the potential of artificial intelligence in drug discovery and development, machine learning and patient monitoring
Benefit from updates in Protein, Antibodies, Peptides and Cell based biotherapeutic development
Maximising your knowledge on the key discovery and development strategies in Immunotherapy, Immuno-oncology, Biologics
and Microbiome
Identifying the key technologies in accelerating the genomics revolution
Exploiting Biomarker technologies in clinical development, precision medicine and targeted therapy
Evaluating and overcoming the challenges of finding and funding innovation for Biotech spinoffs
Gaining insights from the Partnering and Licensing Innovations in the Pharma & Biotech industry
Attendee Benefits
Do not miss out on presenting on the speaker programme, featuring presentations by:
✓ Emerging university spin offs and entrepreneurial companies to access to interested VC funds and investors
✓ Academic researchers and technology transfer offices to present an IP or idea to funding and development partners
✓ Biotech companies to partner their products, form alliances and develop global financing contacts
For speaking opportunities, please email [email protected]
➢ Advancing to the clinic: antibody drug conjugates
➢ Innovative design and engineering approaches
➢ Fusion protein therapeutics
➢ New targets & new indications for protein biotherapeutics
➢ Accelerating antibody discovery & optimisation:
➢ Bispecific antibodies
➢ Monoclonal antibodies
➢ Antibody drug conjugates
DAY 2 – Stream 3
Biomarkers/Precision Medicine/ Liquid Biopsy in Drug and
Clinical Development
08.00-08.30
Keynote Address- Addressing R&D Innovation in GSK
• Therapeutic areas in focus
• Partnering and open innovation
Paul-Peter Tak, Senior Vice President R&D Pipeline, Global Development Leader and Chief Immunology Officer,
GSK
08.30-09.00
Panel Discussion - Artificial Intelligence and Digital Health
• Analysis of the Artificial Intelligence market: Drug Discovery and Development, Machines Learning and
Patient Monitoring
• Digital healthcare and integrated healthcare
Panellists: Vijay Barathan, Life Science Partner, Catapult Ventures(Reserved)
09.00-09.30
Panel Discussion - Accelerating Genomics Revolution
• Adoption of NGS
• Moving to single-cell biology
• Clinical Diagnostics
• cell-free DNA
• dPCR
• Microfluidics
Panellists: Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics
Michael Fraser, VP University Relations, Queen's University
Arbieva, Zarema, Director of Research Service Facility - Core Genomics Facility, CGF
EMD Serono
09.30-10.00
Panel Discussion - Innovation in the Pharma & Biotech – Partnership and Licensing
• Innovation in practice – how partnerships are formed in Pharma
• The latest drug research and development efforts, success and paths to commercialisation
Panellists:
Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer
10.00-10.30 Morning Refreshment Break
Stream 1: NGS/Genomic
Technologies/dPCR/ Microfluidics
Stream 2: Drug Discovery
and Development –
Microbiome, Immuno-
oncology, Oncology
Stream 3: Pharma IT,
Artificial Intelligence,
Medical Devices, and
Digital Health
Scheduled
Partnering
Meetings x8 and
Exhibition
10.30-10.45
Laura Roca-Alonso, Chief Business
Officer, Silence Therapeutics
Spinoffs and emerging
biotech company
presentation
AI and Variant Classification
In Rare Disorder Diagnostics
Tommi Lehtonen, CEO,
Blueprint Genetics
10.45-11.00
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.00-11.15
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.15-11.30
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.30-11.45
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.45-12.00
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
12.00-12.15
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
DAY 1 Agenda At A Glance
12.15-12.30
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
12.30-13.30 Lunch
Stream 1: NGS/Genomic
Technologies/dPCR/ Microfluidics
Stream 2: Drug Discovery
and Development –
Microbiome
Stream 3: Pharma IT,
Artificial Intelligence,
Medical Devices, and
Digital Health
13.30 – 14.00
Single Cell Analysis - Translation
to Diagnostic and Therapeutic
Applications
Microbiome Discovery
and Development
Johan van Hylckama Vlieg,
Vice President Microbiome
and Health Innovation, Chr-
Hansen A/S (Invited)
Machine Learning and
Sequence Analysis As
Enablers Of RNA Drug
Discovery
Morten Lindow, Director,
Innovation and Project
Excellence, Roche
Scheduled
Partnering
Meetings x9 and
Exhibition
14.00 – 14.30
NGS Data Analysis & NGS
Application Strategies
Natasha Carli,
Genomics Core Director, Gladstone
Institutes
Microbiome and Drug
Discovery Case Study
Patrice Garnier, CEO,
AMABIOTICS
AI and Precision medicine
Ron Alfa, VP of Discovery
and Product,
Recursion Pharmaceuticals
14.30 – 15.00
Collaborative Phenotyping at
King’s College London: HipSci and
the Stem Cell Hotel • Characterisation of a large panel of
Human Induced Pluripotent Stem
Cells (see www.hipsci.org)
• Integration of High Content imaging
with other datasets such as genomics,
transcriptomics, proteomics
• Opening of a collaborative
phenotyping space to internal and external scientists and technology
providers
Davide Danovi, Director, HipSci
Cell Phenotyping, Centre for Stem
Cells & Regenerative Medicine,
King's College London
Microbiome and Drug
Discovery Case Study
Kristin Wannerberger,
Director R&D Alliance
Management, Ferring
International Center S.A
Machine Learning and
Data Analysis
15.00 – 15.30
NGS, Genomics And Clinical
Diagnostics In Healthcare
Microbiome and Drug
Discovery Case Study
Assaf Oron, Chief Business
Officer, BioimX
Medical Devices And
Digital Healthcare
Solutions
15.30 – 16.00
Panel Discussion: Join our keynote panellists as they address
the challenges of finding and funding innovation for biotech
spinoffs
• De-risking biotech projects in the university environment
prior to spinout or licence – a good or bad idea?
• The importance of patient capital for early stage biotech
investments
• Other models of funding therapeutic development projects
(e.g. Licensing funds and project aggregators)
Tony Hickson, MD, Imperial Innovations Ltd
Start Up Slam Event – 5 pitches
16.00-16.30 Afternoon Refreshments
DAY 1 Agenda At A Glance
16.30-17.00
Panel Discussion: Microbiome Discovery and Development
• What are the most successful microbiome trends with clear
therapeutic potential?
• What are the potential challenges of microbiome drug
development?
Moderator:
Avi Spier, Director, NIBR BD&L, Search and Evaluation, CVM,
GDC, CBT Chem-Bio, GNF Systems and Microbiome, Novartis
(reserved)
Panellists:
Maciek Drozdz, Principal of Venture Investments Johnson and
Johnson Development Corporation
Kristin Wannerberger, Director R&D Alliance Management,
Ferring International Center S.A
Bernhard Paetzold, Founder, S-Biomedic
Patrick Gillevet, Professor, Director, George Mason University,
Director of the Microbiome Analysis Center
Department of Biology and MicroBiome Analysis Center, George
Mason University
Start Up Slam Event – 5 pitches
17.00-17.30
Innovations of NGS In Pharma: Biomarker Development,
Precision Medicine And Clinical Diagnostics
17.30-18.00
Single Cell Data Analysis & Advances in Microfluidic
Technologies
Christopher Roberts, Associate Director of Computational
Biology, Biogen Idec
18.00 – 18.30
AI in Cloud computing and Big data
18.30-19.45 Drinks Reception
19.45-21.00 Sponsored Awards Dinner
END OF DAY ONE
Featured Event at the Showcase : Start Up Slam
At the showcase event, there are two dedicated sessions on the agenda for start-up entrepreneurs or
scientists like yourselves to present your new product and research in front of leading pharma and biotech
venture companies, VCs and Technology Transfer offices. If you are developing an innovative product or
technology in the following areas, please email [email protected]
• NGS/Single Cell/Genomics Technologies/dPCR/Microfluidics
• Microbiome Discovery and Development
• Pharma Technologies, Artificial Intelligence, Medical Devices and Digital Health
• Immuno-Oncology and Immuno-Therapy Drug Discovery and Development
• Biomarkers/Precision Medicine/ Liquid Biopsy in Drug and Clinical Development
• Proteins, Antibodies, Cell Therapeutic Development
08.00-08.30
Keynote Address – Biomarker Clinical Market Development, Companion Diagnostics Development
And Targeted Therapy
08.30-09.00
Panel Discussion - Accelerating Antibody Discovery & Optimisation:
o Bispecific antibodies
o Monoclonal antibodies
o Antibody drug conjugates
Panellists:
Mihriban Tuna, Vice President, Drug Discovery, F-star Biotechnology Ltd.
09.00-09.30
Panel Discussion - Precision Medicine/Liquid Biopsy/Targeted Patient Treatment
Panellists:
Yiu-Lian Fong, Global Head Diagnostic Innovation, Research and Early Development, Johnson and Johnson
Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance Management Healthcare Business, EMD Serono
Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.
09.30-10.00
Special Address: Updates on Immuno-Oncology Discovery and Development Trends
Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment,
Medimmune
10.00-10.30 Morning Refreshment Break
Stream 1: Drug Discovery
and Development -
Immuno-Oncology and
Immuno-Therapy
Stream 2: Proteins,
Antibodies, Cell
Therapeutic
Development
Stream 3:
Biomarkers/Precision
Medicine/Liquid Biopsy in
Drug Development and
Clinical Trials
Scheduled Partnering
Meetings x8 and
Exhibition
10.30-10.45
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
10.45-11.00
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.00-11.15
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.15-11.30
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.30-11.45
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
11.45-12.00
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging
biotech company
presentation
12.00-12.30
Panel Discussion – Market Outlook for Immuno-oncology investment
Recent Deal Trends In Immuno-Oncology
• From the Biotech perspective: funding environment, partnerships and exits
• From the Pharma side: deal trends and emerging innovation
• Strategies and tactics for combination therapies
Moderator:
Timothy Herpin, Vice President, Head of Transactions, Business Development,
AstraZeneca
Panellists: John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.
12.30-13.30 Lunch
DAY 2 Agenda At A Glance
Stream 1: Drug Discovery
and Development -
Immuno-Oncology and
Immuno-Therapy
Stream 2: Proteins,
Antibodies, Cell
Therapeutic
Development
Stream 3: Clinical
Development, Biomarkers,
Precision Medicine
Scheduled Partnering
Meetings x9 and
Exhibition
13.30-14.00
Immuno-oncology
Therapeutic Development
Richard C.A. Sainson,
Director in Pharmacology
and Translational Sciences,
Kymab
Antibody Engineering,
Design & Development
Approaches
Biomarkers And Liquid
Biopsy
Jun Huang, Associate
Director, R&D and BioPharma
Solutions, Admera Health,
LLC (Invited)
14.00 – 14.30
Immuno-oncology Clinical
Development - ImmTACs
Bent Jakobsen, Chief
Scientific Officer, Immunocore
Human Protein
Therapeutics
Pierre-Jean Ripoll,
Director R&D France,
Pharming Group
Precision Medicine,
Companion Diagnostics,
Molecular Diagnostics
Development
14.30 – 15.00
Car T Cells For The
Treatment Of Cancer
• Status of clinical trials
• Manufacturing of Car T
cells
• Future of Car T cell
treatments
Lothar Germeroth, Senior
Vice President Juno
Therapeutics Inc., Managing
Director Juno Therapeutics
GmbH
GAGbodies: a new class
of biotherapeutics
targeting glycans in
immuno-oncological indications
Andreas Kungl, CEO,
Antagonis
Precision Medicine And The
Role of Biomarkers in
Clinical Development
Philip M. Arlen, President &
Chief Executive Officer,
Precision Biologics, Inc.
15.00 – 15.30
Cancer Immunoassays for
Biomarker Development
Cutting Edge
Technologies For
Antibody Discovery
Data Integration Methods
15.30 – 16.00 Afternoon Refreshments
16.00-16.30
Clinical Trial Design And
Management
Peptide Discovery and
Development
Innovative Biology- NGS &
Genomic Markers, Clinical
Testing and Diagnostics
Development
16.30-18.30 Start Up Slam x 5 Pitches
END OF SHOWCASE
Day Two Agenda At A Glance
BOOKING FORM HOW TO REGISTER:
FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: [email protected]
Please complete fully and clearly. Please photocopy for additional delegates Title: …………………………… Forename: ………………………………………………….. Surname: …………………………………………………... Company/Organisation: …………………………………………………………………………………………………………………………………………. Job Title: …………………………………………………………………………………………………………………………………………………………... Address: ……………………………………………………………………………………………………………………………………………………………. Postcode: …………………………... Country: …………………………... Direct Telephone: ………………………………... Mobile: …………….…………….. Switchboard: ……………………….. Fax: ……………………….. Email: ……………………………………………………………………………………………………………………………………………………………….. Signature: ………………………………………………. Date: ……………………………………………………..
Number of delegates:
CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:
Valid from: /
Expiry Date: /
Security code:
Cardholders name ………………………………………...
Signature: …………………………………………………. Date: ……………………………………….
PLEASE INVOICE ME:
Invoice Address (if different from above) ……………………………………………………………………… ……………………………………………………………………… ……………………………………………………………………... PO Number (if applicable) ………………………………………. * Please note there is a £50 plus VAT handling charge for payment via invoice * All card payments will be subject to a 3% bank charge or 4% AMEX charge * Payment to be made within 30 days of invoice
Registration Fees
Delegate Details
How to Pay (choose one of the following payment options)
I would like to attend: (Please tick as appropriate) REGISTRATION AND PARTNERING ACCESS (FULL PASS) • Full access to the 1-2-1 networking portal pre-event • Up to 17 Meetings per day (34 meetings over 2 days) • 1x full conference pass
Academic Spinoffs, Biotech spinoffs, TTOs: £950+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,
Solution Providers: £2450+VAT POSTER PRESENTATION • 1x A0 portrait poster display in exhibition hall (must register for full pass)
Academic Spinoffs, Biotech spinoffs, TTOs:
£150+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,
Solution Providers: £250+VAT SPEAKER PRESENTATION • 15 Minute presentation platform in conference room (must register for full pass)
Academic Spinoffs, Biotech spinoffs, TTOs: £250+VAT
VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors, Solution Providers: £1000+VAT EXHIBITION • 2x2m table-top in main Exhibition Hall (must register for full pass)
Academic Spinoffs, Biotech spinoffs, TTOs:
£500+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,
Solution Providers: £1000+VAT
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected] www.biotechinvestment-showcase.com
Terms & Conditions of Booking
I agree to the terms and conditions (Please refer to page 2 for the terms and conditions)
To obtain information on our full sponsorship opportunities, please contact [email protected]
Sponsorship Opportunities
Terms & Conditions of Booking
1. Definitions In these terms and conditions, the following terms have the following meanings: - “Contract Price” The total cost payable for the Package as shown on the official booking form “Delegate/Sponsor” Any person who has been invited by the Organisers to attend the showcase, start up slam and partnering meetings OR Any company or person who has purchased a package or any agent representative or employee of such company or person “Event” named in the Terms and Conditions Title above "Meeting Area" The meeting area/exhibition space designated for the Sponsor/Exhibitor at the Event “Organisers” Oxford Global Marketing Limited “Package” The accommodation, area for meetings and conference sessions in a hotel venue where the Event will take place in-cluding meals but not beverages unless specified by the Organiser. 2. Law These terms shall be construed in accordance with English law and subject to the exclusive jurisdiction of the English courts. 3. Application for Packages Applications must be made on the Organiser’s official booking form, which must be completed in full. The Organisers may accept applications in writing, by email or facsimile, or accept a deposit payment in lieu of written application at their sole discretion, and on the understanding that these terms and conditions apply to any application and supersede any terms and conditions of the Delegate/Sponsor. Any alterations of these terms and conditions cannot be accepted without the prior written consent of a direc-tor of the Organiser. 4. Payment The Delegate/Sponsor shall pay the contract price in accordance with the dates set out in the official booking form. If any of the above payments shall be 30 days in arrears whether demanded or not, the contract may at any time thereafter be terminated forthwith by the organisers by notice in writing to these parties. Upon termination all instalments paid shall be forfeited and the balance shall become immediately payable. Such termination shall not prejudice any rights or claims by the Organisers against these parties in respect of any prior breach. 5. Contract and Termination On the acceptance of the official booking form by the Organisers, a contract relating to the package purchased by the Delegate/Sponsor will exist between these parties and the Organisers as set out in these terms and conditions. In case of non payment of any sum due from these parties whether legally demanded or not, or of the breach, or non-observance, by these parties of any of these terms and conditions, or any regulations to be observed by these parties, the Organisers shall have the right to terminate the contract and to remove and exclude these parties from the Event without prejudice to the right to recover all sums payable by these parties and all other claims against it, and any loss of damage sustained by the Organisers. 6. Withdrawal or Cancellation In the event of withdrawal or cancellation, the following amounts shall become immediately payable: More than 6 months prior to the event 35% cancellation fee Between 6 and 3 months prior 75% cancellation fee Less than 3 months prior to the event full cancellation fee Any notification of withdrawal or cancellation must be in writing and sent to the Organisers by recorded delivery. Cancellation will be deemed to have occurred when written notification has been received by the Organisers. 7. Occupation of Meeting Area The Delegate/Sponsor (subject to contracted package) must occupy their allocated Meeting Area by the Event opening time on the first day of the Event. Failing to do so will be deemed a cancellation of Package, in which case the terms and conditions relat-ing to withdrawal or cancellation will apply, and the Package may be offered to another Delegate/Sponsor. 8. Bankruptcy In the event of bankruptcy, liquidation, having an administrator or receiver appointed, or entering into a voluntary arrangement with its creditors; the Delegate/Sponsor’s contract may be terminated at the option of the Organisers and the full contract price will be due and payable forthwith. 9. Prohibition of Transfer A Delegate/Sponsor may not assign, sublet or share possession of, or grant licenses in respect of the whole or any part of the Package nor may any cards, advertisements, or printed matter of firms who are not bona fide Delegate/Sponsor’s be exhibited in or distributed from any area. This does not apply to firms which are subsidiaries, agents or principals of the Solution Provider and which are duly listed on the official application form at the time of booking.
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]
Terms & Conditions of Booking
10. Postponement or Abandonment The Delegate/Sponsor shall not have any claim against the Organisers in respect of any loss or damage consequent upon the failure for whatever reason to hold any part of the Event or if the hotel venue at which the Event is scheduled to take place be-comes wholly or partially unavailable for the holding of the Event. If, by the re-arrangement or postponement of the period of the Event, or by substitution of another hotel venue for the holding of the Event, or any other reasonable action, the Event can take place, the contract shall remain in force. If the Organisers abandon the Event other than by reason of events or circumstances beyond its reasonable control, the Organisers will reimburse the Contract Price. If the Event is abandoned by the Organisers by reason of events or circumstances beyond it’s reasonable control, the Organiser will reschedule the Event (to be held within 12 months of the original event) but no reimbursement will be made by the Organiser and the Delegate/Sponsor will remain liable to pay the Contract Price. 11. Liability Save in the case of death or personal injury caused by the Organisers' negligence, the Organisers are not responsible for the health & safety of any meeting or conference or any property of the attendees or any third party, or for any loss or damage sus-tained by these parties or any third party, in each case for any reason whatsoever. Delegates/Sponsors should have in place their own insurance to cover all such liabilities and risks. 12. Event Promotional Materials Only the signage provided by the Organisers will be used by the Delegate/Sponsor. The Organisers will notify the Delegate/Sponsor of the nature of available meeting facilities and of promotional material e.g. display stands and brochures that they may display. The Organisers reserve the right (without being required to give notice) to alter the layout of any meeting floor plan at any time and to relocate these parties to another area. 13. Information and Copyright Information supplied by the Organisers in relation to any event is accurate to the best of their knowledge and belief, but shall not constitute any warranty or representation by the Organisers and any inaccuracy or mistake in such information or omission from it shall not permit the Delegate/Sponsor to cancel a confirmed booking. All information and data relating to the Event, which is supplied by the Organisers to the Delegate/Sponsor is the copyright of the Organisers and cannot be passed on to any third party for any purpose. The Organiser processes information about each Delegate/Sponsor in accordance with the Organiser's privacy policy, a copy of which is available on our website or by written request. By submitting information to the Organiser, the Delegate/Sponsor con-sents to such processing and warrants that all data provided is accurate 14. Substitution The Delegate/Sponsor may substitute a representative up to 3 weeks before the event provided that this is conveyed via email to the Organiser and also by completing a new on-line application form and stating in the relevant box on the form the name of the person s/he is replacing. The replacement Delegate/Sponsor will take over the partnering meetings agreed by the original party, although these can be cancelled if the meetings are no longer relevant.
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]